Summary
A computational platform modeled protein dynamics to identify hidden allosteric and cryptic binding sites linked to misfolding diseases. It designed small molecule correctors in silico to restore normal protein function. This approach moved beyond static structure-based discovery, reducing reliance on traditional high-throughput screening. The result was a scalable pipeline strategy for difficult-to-drug targets and partnership-ready assets.